Home

Vanda Pharmaceuticals Inc. - Common Stock (VNDA)

4.5300
+0.0500 (1.12%)

Vanda Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative therapies to address unmet medical needs in the fields of central nervous system disorders and sleep disorders

The company is dedicated to improving the lives of patients through its specialized drug products, which aim to treat conditions such as schizophrenia and insomnia. Vanda's research and development efforts are primarily geared towards advancing its pipeline of proprietary medicine, leveraging scientific expertise and clinical insight to enhance treatment options for patients around the world.

SummaryNewsPress ReleasesChartHistoricalFAQ
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
WASHINGTON and SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab (IL-36R antagonist mAb), which has successfully completed two registration-enabling global Phase 3 trials, GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of imsidolimab in patients with Generalized Pustular Psoriasis (GPP).
By AnaptysBio, Inc. · Via GlobeNewswire · February 3, 2025
Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) concerning the Company and its directors’ and officers’ possible violations of state laws.
By Glancy Prongay & Murray LLP · Via Business Wire · December 16, 2024
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves targeted at specific brain regions and has shown promise in easing symptoms for patients with treatment-resistant bipolar disorder.1 Initially approved for major depressive disorder by the FDA, iTBS offers … Continue reading "Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment"
Via PressReach · August 6, 2024
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) Near the Top of Equities by Percentage Gain on 4/3
Vanda Pharmaceuticals Inc. (NASDAQVNDA) is one of today’s top gainers. The company’s shares have moved 37.98% on the day to $5.39.
Via Investor Brand Network · April 3, 2024
Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) concerning the Company and its directors’ and officers’ possible violations of state laws.
By Glancy Prongay & Murray LLP · Via Business Wire · June 10, 2024
Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals
Reminds Vanda’s Board of Their Fiduciary Duties Given the Mishandling of Future Pak’s Offer to Acquire Vanda’s Underperforming and Undervalued Shares at an ~80-90% Premium
By Shareholder Capital LLC · Via GlobeNewswire · April 25, 2024